Senti Biosciences Holdings annual free cash flow
2021
2022
2023
2024
2025
Senti Biosciences Holdings Free Cash Flow (FCF) History (SNTI)
Senti Biosciences Holdings reported −$43.6M in free cash flow for fiscal 2025, a decrease of $2.2M from the previous fiscal year, with a free cash flow margin of −198363.64%.
View full Senti Biosciences Holdings company overviewSenti Biosciences Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$43.6M | −$2.2M | — | −198363.64% |
| 2024 | 2024-12-31 | −$41.4M | $23.0M | — | — |
| 2023 | 2023-12-31 | −$64.4M | $11.8M | — | −3257.48% |
| 2022 | 2022-12-31 | −$76.3M | −$36.1M | — | −2321.06% |
| 2021 | 2021-12-31 | −$40.2M | — | — | −1753.73% |
Senti Biosciences Holdings quarterly free cash flow
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −$6.9M | $6.6M | — | — |
| Q3 2025 | 2025-09-30 | −$9.4M | −$1.6M | — | — |
| Q2 2025 | 2025-06-30 | −$13.3M | −$4.9M | — | — |
| Q1 2025 | 2025-03-31 | −$14.1M | −$2.4M | — | — |
| Q4 2024 | 2024-12-31 | −$13.5M | −$6.5M | — | — |
| Q3 2024 | 2024-09-30 | −$7.9M | $9.4M | — | — |
| Q2 2024 | 2024-06-30 | −$8.3M | $9.0M | — | — |
| Q1 2024 | 2024-03-31 | −$11.7M | $11.1M | — | — |
| Q4 2023 | 2023-12-31 | −$7.0M | $10.5M | — | — |
| Q3 2023 | 2023-09-30 | −$17.2M | $7.1M | — | −6759.61% |
| Q2 2023 | 2023-06-30 | −$17.3M | −$389,000 | — | −2524.60% |
| Q1 2023 | 2023-03-31 | −$22.8M | −$5.4M | — | −2201.83% |
| Q4 2022 | 2022-12-31 | −$17.5M | −$16.5M | — | — |
| Q3 2022 | 2022-09-30 | −$24.3M | — | — | −1605.34% |
| Q2 2022 | 2022-06-30 | −$17.0M | — | — | −1530.23% |
| Q1 2022 | 2022-03-31 | −$17.4M | — | — | −2042.04% |
| Q3 2021 | 2021-09-30 | −$1.0M | — | — | −112.78% |
Senti Biosciences Holdings free cash flow growth trends
Senti Biosciences Holdings's latest reported quarter, Q4 2025, generated −$6.9M in free cash flow, an increase of $6.6M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Senti Biosciences Holdings filings at SEC.gov ↗